Clinical Trials
605 trialsNCT00186641 2026-06-05
High Dose Chemotherapy and Autologous Transplant for Breast Cancer
Stanford University
Phase 2 Completed
NCT01702831 2026-06-05
BuMelMCRN001
University Health Network, Toronto
Phase 2 Completed
NCT02738866 2026-06-05
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03525262 2026-06-05
POTEN-C
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT03526432 2026-06-05
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
University of Oklahoma
Phase 2 Active not recruiting
NCT03918252 2026-06-05
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT04074096 2026-06-05
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting
NCT04188405 2026-06-05
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04322955 2026-06-05
Cyto-KIK
Columbia University
Phase 2 Active not recruiting
NCT04481048 2026-06-05
DoDNAC
Children's Hospital Medical Center, Cincinnati
Phase 2 Completed
NCT04529044 2026-06-05
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
OHSU Knight Cancer Institute
Phase 2 Recruiting
NCT04632459 2026-06-05
Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer
Samsung Medical Center
Phase 2 Completed
NCT04747912 2026-06-05
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
Phase 2 Recruiting
NCT05035836 2026-06-05
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05110781 2026-06-05
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
University of California, Davis
Phase 2 Terminated
NCT05168618 2026-06-05
AtezoCab
University of Utah
Phase 2 Recruiting
NCT05379972 2026-06-05
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
University of Colorado, Denver
Phase 2 Completed
NCT05405387 2026-06-05
IMPACT
University of Utah
Phase 2 Recruiting
NCT05723055 2026-06-05
NAHL
University of Utah
Phase 2 Active not recruiting
NCT05916196 2026-06-05
[18F]FES PET/.CT in Uterine Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT05941325 2026-06-05
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Shanghai 6th People's Hospital
Phase 2 Suspended
NCT06057948 2026-06-05
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06084780 2026-06-05
TRANSCAPE
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT06214793 2026-06-05
Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)
Case Comprehensive Cancer Center
Phase 2 Suspended
NCT06290687 2026-06-05
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT06381830 2026-06-05
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Terminated
NCT06482515 2026-06-05
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
University of Maryland, Baltimore
Phase 2 Recruiting
NCT06499870 2026-06-05
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT06630221 2026-06-05
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Case Comprehensive Cancer Center
Phase 2 Suspended
NCT06765317 2026-06-05
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06771518 2026-06-05
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Regina Elena Cancer Institute
Phase 2 Recruiting
NCT06880289 2026-06-05
Chemo-Radiotherapy Boost Treatment Guided by Perfusion MRI on Hypoxic Zones in Head and Neck Cancer
Regina Elena Cancer Institute
Phase 2 Active not recruiting
NCT07039526 2026-06-05
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07071961 2026-06-05
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT07164469 2026-06-05
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07194980 2026-06-05
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT07226453 2026-06-05
PNOC041
University of California, San Francisco
Phase 2 Recruiting
NCT07485452 2026-06-05
OSIBBBOOST
Maastricht University Medical Center
Phase 2 Recruiting
NCT07510334 2026-06-05
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Mayo Clinic
Phase 2 Recruiting
NCT07527325 2026-06-05
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
University of California, Irvine
Phase 2 Not yet recruiting
NCT07624487 2026-06-05
Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma
Taipei Medical University Hospital
Phase 2 Not yet recruiting
NCT07628738 2026-06-05
A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
Ruijin Hospital
Phase 2 Recruiting
NCT07629609 2026-06-05
BEFAST
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT07630077 2026-06-05
Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07630103 2026-06-05
Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07630168 2026-06-05
TIMED
UNC Lineberger Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07631000 2026-06-05
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07631052 2026-06-05
Capecitabine in ER+/HER2-negative Breast Cancer
University Health Network, Toronto
Phase 2 Recruiting
NCT00609791 2026-06-04
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02286726 2026-06-04
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed